Impaired structural correlates of memory in Alzheimer's disease mice  by Badhwar, AmanPreet et al.
NeuroImage: Clinical 3 (2013) 290–300
Contents lists available at ScienceDirect
NeuroImage: Clinical
j ourna l homepage: www.e lsev ie r .com/ locate /yn ic lImpaired structural correlates of memory in Alzheimer's disease miceAmanPreet Badhwar a,1, Jason P. Lerch b,c,1, Edith Hamel a,⁎, John G. Sled b,c,⁎⁎
a Laboratory of Cerebrovascular Research, Montreal Neurological Institute, McGill University, Montréal, QC H3A 2B4, Canada
b Mouse Imaging Centre, Hospital for Sick Children, Toronto, ON M5T 3H7, Canada
c Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 2M9, Canada⁎ Correspondence to: E. Hamel, Laboratory of Cereb
Neurological Institute, Montréal, QC H3A 2B4, Canada. Te
514 398 8106.
⁎⁎ Correspondence to: J.G. Sled, Mouse Imaging
Phenogenomics, Toronto, ON M5T 3H7, Canada. Tel.: +
837 5832.
E-mail addresses: edith.hamel@mcgill.ca (E. Hamel), jo
1 Contributed equally.
2213-1582 © 2013 The Authors. Published by Elsevier Inc
http://dx.doi.org/10.1016/j.nicl.2013.08.017a b s t r a c ta r t i c l e i n f o Article history:
Received 20 June 2013
Received in revised form 14 August 2013
Accepted 30 August 2013
Available online 6 September 2013
Keywords:
Alzheimer's disease
Mouse model
Magnetic resonance imaging
Memory
Neuroanatomical plasticity
Pioglitazone-treatmentThe healthy adult brain demonstrates robust learning-induced neuroanatomical plasticity. While altered neuro-
anatomical plasticity is suspected to be a factor mitigating the progressive cognitive decline in Alzheimer's dis-
ease (AD), it is not known to what extent this plasticity is affected by AD. We evaluated whether spatial
learning and memory-induced neuroanatomical plasticity are diminished in an adult mouse model of AD (APP
mice) featuring amyloid beta-driven cognitive and cerebrovascular dysfunction. We also evaluated the effect
of early, long-termpioglitazone-treatment on functional hyperemia, spatial learning andmemory, and associated
neuroanatomical plasticity. Using high-resolution post-mortem MRI and deformation-based morphometry, we
demonstrate spatial learning and memory-induced focal volume increase in the hippocampus of wild-type
mice, an effect that was severely attenuated in APP mice, consistent with their unsuccessful performance in
the spatial Morris water maze. These ﬁndings implicate impaired neuroanatomical plasticity as an important
contributing factor to cognitive deﬁcits in the APP mouse model of AD. Pioglitazone-treatment in APP mice
completely rescued functional hyperemia and exerted beneﬁcial effects on spatial learning and memory-recall,
but it did not improve hippocampal plasticity.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license. 1. Introduction
Spatial learning and recall are disrupted early in the course of
Alzheimer's disease (AD) and worsen with disease progression (Amieva
et al., 2005; Henderson et al., 1989). A potential mechanism that may
contribute to these deﬁcits is loss of learning and memory-induced neu-
roanatomical plasticity. The anatomical structure of the healthy adult
human brain is plastic, and demonstrates both short- and long-term
learning-induced remodeling that is detectable as volumetric differences
on MRI (Draganski et al., 2004; Maguire et al., 2000). Speciﬁcally, neuro-
anatomical plasticity in response to long-term spatial learning and recall
was demonstrated in successful London taxi driver trainees, who at the
end of their training demonstrated greater grey matter (GM) volume
in the posterior hippocampi compared to unsuccessful trainees and
non-taxi-driving controls (Woollett and Maguire, 2011). Recently, using
high-resolution in situ post-mortem MRI and deformation-basedrovascular Research, Montreal
l.: +1 514 398 8928; fax: +1
Centre, Toronto Centre for
1 647 837 5818; fax: +1 647
hn.sled@utoronto.ca (J.G. Sled).
.Open access under CC BY-NC-ND licenmorphometry (DBM), we showed speciﬁc growth in the dorsal hippo-
campus (equivalent to posterior hippocampus in human) of mice trained
for ﬁve days on the spatial Morris water maze (MWM) (Lerch et al.,
2011a). To date, it is not known to what extent learning and memory-
induced hippocampal plasticity is affected in transgenic mouse models
of AD.
Cerebral blood ﬂow (CBF) insufﬁciency has been associated with al-
tered learning andmemory (Iadecola, 2004). Its early appearance in AD
has raised the question as to whether hypoperfusion contributes to the
cognitive decline (Zlokovic et al., 2005). Cognitive task-induced regional
CBF increase is attenuated in at-risk individuals (Xu et al., 2007) and in
AD patients (Peters et al., 2009). These observations, and the ﬁnding
that CBF insufﬁciency can negate the effects of memory enhancing
agents (Yoshida et al., 2007), suggest that therapy that improves CBF
and leads to a better blood supply to neurons could potentially improve
memory in AD (Li et al., 2011; Yoshida et al., 2007).
One such candidate is the drug pioglitazone, an agonist at the perox-
isome proliferator-activated receptor gamma (PPARγ). Pioglitazone is
safe to administer to AD patients (Geldmacher et al., 2011) and was
shown to improve cognition and cerebral perfusion in mild AD patients
with type II diabetes mellitus (T2DM) (Sato et al., 2009). We demon-
strated in elderly AD mice that short-term pioglitazone-treatment nor-
malized cerebrovascular function, but not cognitive performance,
possibly due to short treatment duration and the very late stage of the
pathology (Nicolakakis et al., 2008). Given that pioglitazone was also
able to blunt cerebral oxidative stress, glial activation, and cholinergic
denervation, processes strongly associated with AD, we suggested thatse. 
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treatment. In the current study, we assess whether spatial learning and
memory-related neuroanatomical plasticity is diminished in adult APP
mice, and whether early-initiated, long-term pioglitazone-treatment
improves cerebrovascular function, cognitive performance and neuro-
anatomical plasticity.
2. Materials and methods
2.1. Mice
Transgenic mice overexpressing a mutated form of the human amy-
loid precursor protein (APPmice, line J20) and their wildtype (WT) litter-
mates (C57BL/6J) were used in this study. The APP/J20 line carries
one copy of the familial early-onset AD Swedish (670/671KM→ NL) and
Indiana (717V→ F) APP mutations on the C57BL/6J background (Mucke
et al., 2000). The transgene is driven by the platelet-derived growth factor
β promoter, which leads to increased production of APP-derived amyloid
beta (Aβ) peptides. To eliminate sex-associated differences in brain struc-
ture, and potential estrus-cycle-related effects on working memory, only
maleswere used. A total of 135micewere employed, in particular, 58APP
mice and 77 WT littermates. Mice were housed under a 12-hour light-
dark cycle, in a temperature (23 °C) and humidity (50%) controlled
room, with food and tap water available ad libitum. All experiments
were performed in compliance with the Animal Ethics Committee of the
Montreal Neurological Institute (MNI) and the guidelines of the Canadian
Council on Animal Care.
2.2. Drug treatment
A 14 week treatment regime was initiated in ~3-month-old mice
(young mice), an age when Aβ deposition in brain parenchyma is
absent (Mucke et al., 2000). The treatedgroup, consisting of approximate-
ly half the mice (n = 59; WT(pio), APP(pio)), received a pioglitazone-
containing-diet (20 mg/kg/day), while the remaining mice (n = 63;
WT, APP) received non-medicated control diet. In addition, to determine
the early effect of pioglitazone on cerebrovascular function, a 3-day treat-
ment regime was carried out in a small cohort of young mice (n = 13).
2.3. Laser Doppler ﬂowmetry
Laser Doppler ﬂowmetry (LDF) measurements (Transonic Systems
Inc., Ithaca, NY) of evoked CBF change (CBF) in the somatosensory
area of the neocortex in response to sensory stimulation were carried
out as previously described (Nicolakakis et al., 2008) in two separate
cohorts of young (3-month-old) and adult (6-month-old) mice.
Activity-induced increase in CBF was measured in young mice (8 WT,
5 APP) before and after 3-day pioglitazone-treatment to determine (a)
if APP overexpression induced cerebrovascular insufﬁciency is present
in young APP mice, and (b) whether pioglitazone counters this impair-
ment early during the course of treatment. Activity-induced increase in
CBF was measured in adult mice (5 WT, 5 WT(pio), 5 APP, and 4
APP(pio)), where the treated groups received 3-months of pioglitazone,
to determine (a) if cerebrovascular insufﬁciency is persistent, and
(b) whether long-term pioglitazone-treatment rescues this insufﬁcien-
cy.We use the level of activity-induced increase in CBF as a marker of
global cerebrovascular performance. Anesthetized mice (ketamine
85 mg/kg, intra-muscular (i.m.) and xylazine 3 mg/kg, i.m, Wyeth,
St-Laurent QC, Canada) were ﬁxed in a stereotaxic frame and the
bone over the barrel cortex was thinned to translucency for position-
ing of the laser probe. Body temperature was maintained at 37 °C
using a heating pad. Changes in CBF before, during, and after unilat-
eral whisker stimulation (3–6 stimulations, 20 s at 8–10 Hz) were
recorded, with four to six recordings acquired every 30–40 s and av-
eraged for each mouse. Contralateral CBF change was expressed as
percentage increase relative to baseline.2.4. Morris water maze (MWM) training
At the endof treatment, two separate cohorts ofmicewere tested for
5 consecutive days in a circular pool (140 cm diameter) ﬁlled with
water (17 °C ± 1 °C) made opaque with white non-toxic pigment. A
third cohort of mice (15 WT, 13 WT(pio), 7 APP, 7 APP(pio)) served as
non MWM controls. Two versions of the MWM, namely spatial MWM
(8 WT, 7 WT(pio), 8 APP, 8 APP(pio)) and non-spatial MWM (8WT, 8
WT(pio), 7 APP, 7 APP(pio)), that differ with respect to cognitive de-
mand (Lerch et al., 2011a) were used.
2.4.1. Spatial MWM
In the spatial MWM, a circular escape platform (10 cm diameter)
was submerged 0.5 cm below the water surface in a ﬁxed quadrant
(target quadrant), and distal visual cues were available to the mice
during the entire length of the protocol.
2.4.2. Non-spatial MWM
In the non-spatial MWM, the same platform was elevated above
the water surface and marked by a visible cue (a cylinder 4 cm
diameter × 4 cm, sitting on top of the platform). The cued platform was
moved to a different location on each trial. A black curtain surrounded
the pool, obscuring the distal visual landmarks, to minimize reliance on
spatial strategies.
In both mazes, on each training day, mice received six training trials
(presented in two blocks of three trials; inter-block interval was 1 h).
The trial began by placing the mouse into the pool facing the wall, in
one of four pseudo-randomly chosen start locations. The trial was com-
plete once the mouse found the platform or 60 s had elapsed. If the
mouse failed to ﬁnd the platform on a given trial, the experimenter
guided the mouse onto the platform. Spatial memory was assessed on
day 5; 2 h after theﬁnal training trial, using a single 60 s probe trial dur-
ing which the platform was removed from the pool. Movement of mice
in the pool was followed and analyzed with the 2020 Plus tracking sys-
tem andWater 2020 software (Ganz FC62D video camera; HVS Image).
During training (learning phase of the test), we assessed the escape la-
tency (the time to reach the platform) in both mazes over ﬁve days of
training. In addition, for the spatial MWM, we assessed the swim path
distance versus time and the mouse learning capacity using the slopes
of the curves of the escape latencies (Drouin et al., 2011), which quantify
the improvement of escape latency over time as a measure of learning.
Performance in the spatial MWM probe trial was evaluated using cross-
ings over the platform area (an index of memory precision; Morris,
1984), percent distance covered in the target quadrant (an index ofmem-
ory retrieval;Morris, 1984), percent distance covered in non-target quad-
rants, and swim paths. Swim speed was evaluated both during training
and probe trial.
2.5. Magnetic resonance imaging (MRI)
2.5.1. MRI sample preparation
In order to maximize our power to detect learning-related volume
changes in these mice, we acquired high quality images post mortem
with a resolution and contrast not obtainable in vivo (Lerch et al., 2012).
Ten days post-MWM-training, mice were anaesthetized (65 mg/kg
sodium pentobarbital, intra-peritoneal (i.p.)) and transcardially per-
fused with phosphate buffered saline (PBS, 30 ml, pH 7.4, 25 °C)
followed by paraformaldehyde (4% PFA, 30 ml, 25 °C) plus 2 mM
ProHance in PBS. Bodies, along with the skin, lower jaw, ears, and the
cartilaginous nose tip were removed. The remaining skull structures
containing the brain were allowed to postﬁx in 4% PFA plus 2 mM
ProHance at 4 °C for 12 h. The skulls were then transferred to solution
containing PBS, 0.02% sodium azide and 2 mM ProHance for 4 days at
15 °C. Mice serving as nonMWM controls were subjected contempora-
neously to the same procedure.
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A multi-channel 7.0 Tesla MRI scanner (Varian Inc., Palo Alto, CA)
with a 6-cm inner bore diameter insert gradient was used to acquire
anatomical images of brainswithin skulls. Prior to imaging, the samples
were removed from the contrast agent solution, blotted and placed into
plastic tubes (13 mmdiameter) ﬁlled with a proton-free susceptibility-
matchingﬂuid (Fluorinert FC-77, 3MCorp., St. Paul,MN). Three custom-
built, solenoid coils (14 mm diameter, 18.3 cm in length) with over
wound ends were used to image three brains in parallel. Parameters
used in the scans were optimized for grey/white matter contrast
(Lerch et al., 2011a): a T2-weighted, 3D fast spin-echo sequencewas ac-
quired with 6 echoes, with TR/TE = 325/32 ms, four averages, ﬁeld-of-
view 14 × 14 × 25 mm3 and matrix size = 432 × 432 × 780, giving
an image with 32 μm isotropic voxels. Total imaging time was 11.3 h
per scan. The resulting images underwent a non-linear deformation al-
gorithm (Avants et al., 2008) to align, in a blinded manner, correspond-
ing anatomical features among all 103 brain images. This algorithm
proceeded iteratively, aligning the individual images to an evolving av-
erage image that gained anatomical ﬁdelity asmore degrees of freedom
were added to account for the individual anatomical differences. The
ﬁnal deformation ﬁelds that aligned each individual scan to the average
were then analyzed using the Jacobian determinant to compute local
volume change (Lerch et al., 2011b) for each mouse. Cortical thickness
was also measured using a Laplacian thickness algorithm (Lerch et al.,
2008). In addition to the voxel-wise analyses, an anatomical atlas com-
prised of 62 deﬁned regions (Dorr et al., 2008) was used to perform au-
tomated template-based segmentation of regional volumes such that
the same labeled template was applied to each scan (Collins et al.,
1995). Using previously published guidelines (Dorr et al., 2008), this
templatewas augmented to 64 deﬁned regions bymanual segmentation
of hippocampus proper into the CA1, CA2, and CA3 subﬁelds by a single
investigator (A.B.) using the average volume generated from 103
independent mouse brain images. The software Display was used for
manual segmentation (http://www.bic.mni.mcgill.ca/ServicesSoftware
Visualization/HomePage, MNI, Montréal, Canada). The guidelines for
the location and boundaries of CA ﬁelds were obtained using the
Mouse Allen Reference Atlas available online at http://www.brain-
map.org/, The Mouse Brain in Stereotaxic Coordinates (Paxinos and
Franklin, 2001), and CA pyramidal cell density gradient in a manner
similar to published recommendations by Richards et al. (2011).
2.5.3. MRI data analysis
Statistics were performed separately on regional volumes as well as
log Jacobians at every voxel. In each case, we used a heteroscedastic lin-
ear model, implemented using generalized least squares in the NLME
package in R (Pinheiro and Bates, 2000), allowing for different variances
per genotype. The linear model employed consisted of all main effects
and interactions between the factors genotype (APP vs WT), treatment
(pioglitazone vs. non-medicated), and maze training (spatial vs non-
spatial). Multiple comparisons were corrected for using the False Dis-
covery Rate (Genovese et al., 2002).
2.6. Histochemistry and quantiﬁcation of staining
FollowingMR imaging, theﬁxed brainswere removed from the skull
and parafﬁn embedded. Coronal sections (5 μm-thick, 3 sections/
mouse, 3–4 mice/group) taken through the hippocampus underwent
Nissl (5 min in cresyl violet)- or thioﬂavine S (1% solution for 8 min)-
staining. Nissl staining using cresyl violet stains the cell body, in partic-
ular nucleic acids in the cytoplasm, of the neurons blue, and is classically
used to study neuronal cytoarchitectonics (Thompson, 2000).
Thioﬂavine S binds to proteins with a β-pleated sheet conformation
and is a well-established marker of amyloid plaques in the brain
(Elghetany and Saleem, 1988). Sections were observed under a Leitz
Aristoplan light microscope equipped with epiﬂuorescence using an
FITC ﬁlter (Leica). Pictures were acquiredwith a digital camera (Coolpix4500; Nikon) and analyzed with the MetaMorph 6.1r3 software (Uni-
versal Imaging). Images were manually thresholded and areas of inter-
est (midline and lateral parts of the CA1 region of the hippocampus)
demarcated using ﬁxed-area rectangular boxes (Nissl staining at 10×
zoom) or the hippocampus proper (thioﬂavin S) were outlined in low
power images (4× zoom). Per section, the average neuron size was cal-
culated from ten randomly outlined neuronal cell bodies. In order to
minimize the drift in the criteria used to manually outline the neurons
we conducted the entire analyses in one sitting. The ratio of the area oc-
cupied by theNissl-stained neurons in each area, alongwith the average
cell size for each region, was used to calculate the average number of
cells per CA1 subregion using the deﬁned and constant surface area of
the box outline. The area occupied by thioﬂavine S-positive parenchy-
mal plaques was quantiﬁed as the percent surface area occupied in
the delineated hippocampus.
2.7. Statistical analyses
The investigator was blinded for the LDF, non-spatial and spatial
MWM, and histochemistry procedure and analyses. Statistical compari-
sons of LDF, MWM (non-spatial and spatial), and histochemistry (Nissl
staining) data from 6-month-old mice were analyzed by two-way
ANOVA followed by Newman–Keuls post hoc multiple comparison
test (STATISTICA 10), with the exception of thioﬂavin S-stained hippo-
campal Aβ plaque load between APP and pioglitazone-treated APP
mice that was compared using Student's t test (GraphPad Prism 4). Sta-
tistical comparison of LDF data from non-medicated 3-month-old WT
and APPmicewas analyzed by Student's t test for two-group (unpaired,
Bonferroni-corrected), while LDF data post 3 days of pioglitazone-
treatment was analyzed by Student's t test for within-group (paired)
comparisons (GraphPad Prism 4). For all comparisons, a p b 0.05 was
considered signiﬁcant.
3. Results
3.1. Neural activity-evoked CBF in APP and WT mice: genotype and drug
effects
Neural activity-evoked CBF response provides an index of neuro-
vascular coupling. The CBF response evoked by whisker stimulation in
the somatosensory cortex was signiﬁcantly decreased in young APP
mice, as compared to WT littermates (21.2 ± 0.4% vs 29.3 ± 0.9%,
p b 0.05) (Fig. 1A,B), and persisted with age (17.7 ± 1.8% vs 26.8 ±
1.8%, p b 0.01) (Fig. 1C). Average percent ﬂow deﬁcit measured in APP
mice was 27.8% at 3-months of age, and 34.2% at 6-months of age
(Fig. 1B,C). Pioglitazone-treatment fully normalized this response with
as little as 3-days of treatment (Fig. 1B), an effect that was maintained
with long-term treatment (Fig. 1C). A small, but non-signiﬁcant,
enhancing effect on the average percent ﬂow increase was observed
in WT-treated mice (Fig. 1C).
3.2. Learning and memory in APP and WT mice
3.2.1. Genotype effect
In the non-spatial MWM task (visible platform, Fig. 2A), aside from
small but signiﬁcant punctual differences at days 1 and 4, the progres-
sive decrease in escape latency over the ﬁve-day training period was
comparable between WT and APP mice, thus ruling out overt visual,
motor, andmotivational deﬁcits in APPmice. Mice displayed shorter es-
cape latency in the non-spatial MWM compared to the spatial MWM
(Fig. 2B), conﬁrming the challenging nature of the latter despite similar
sensorimotor and motivational requirements in both versions of the
MWM (Lerch et al., 2011a). In the spatial MWM task, progressive de-
crease in escape latency (Fig. 2B), and distance swam prior to locating
the hidden platform(Fig. 2D) over theﬁve-day training periodwere sig-
niﬁcantly different (p b 0.01) between the two genotypes, indicating
Fig. 2. Spatial learning andmemory deﬁcits in APPmice. (A) Allmice undergoing non-spatialMorriswatermaze performed equallywell at the end of training. (B) In contrast, 6-month-old APP
mice ( )were impaired in the spatialMorriswatermaze, featuring signiﬁcantly longer escape latencies in ﬁnding the hidden platform relative toWT controls ( ). Pioglitazone slightly, but not
signiﬁcantly, improved learning performance in treated APP mice ( ). (C) Compared toWTmice, learning capacity while impaired in APP mice was similar in pioglitazone-treated APP mice.
(D) A decrease in the average distance swam per training daywas observed in pioglitazone-treated APPmice compared to untreated APPmice, reaching signiﬁcance on day 5. (E) In the probe
trial, the number of crossings was slightly higher in pioglitazone-treated APP mice compared to APP mice, but still signiﬁcantly different from WT mice. (F) Compared to WT mice, distance
travelled in the correct quadrant was signiﬁcantly lower in APP, but not in pioglitazone-treated APP mice. (G) Representative swim paths ( start, end) and percent distance travelled in
each quadrant. Pioglitazone-treated APPmice showedmild improvement in the swim strategy used to locate the hidden platform. Overall, all groups displayed comparable swim speeds ruling
outmotor disabilities. Statistical analysis usedwas a two-wayANOVA. p b .05 compared toAPP, p b .05, p b .01, and p b .001 compared toWT. Pioglitazone-treatedWTmice ( ), error
bars: SEM, pio: pioglitazone, WT: wild-type.
Fig. 1. Activity-induced CBF deﬁcits in APP mice are normalized by pioglitazone. CBF changes were measured in the somatosensory cortex before and during whisker stimulation using
laser Doppler ﬂowmetry in 3-month and 6-month-old mice. Activity-induced CBF increase in 3-month-old APP mice ( , n = 5) was reduced compared to WT mice ( , n = 8),
shown using (A) average LDF tracings for the entire 20 second stimulation period, and (B) overall means of the maximal percent change of CBF from baseline. Statistical analysis used
was an unpaired two-tailed t-test (Bonferroni corrected). After 3 days of pioglitazone-treatment, the evoked CBF response measured in the same APP mice ( ) was normalized completely,
and remained unchanged in the WT mice ( ). Statistical analysis used was a paired two-tailed t-test. (C) Compared to untreated WT mice ( , n = 5), the deﬁcit in the activity-induced CBF
response was present in 6-month-old untreated APP mice ( , n = 5). The activity-induced CBF response in 6-month-old APP mice ( , n = 4) treated for 3 months with pioglitazone did
not differ from untreated and treated WT mice ( , n = 5), as shown using a two-way ANOVA. p b 0.05, p b 0.01, p b 0.001. Shaded area on line tracings in (A) deﬁne the SEM at
each point. Error bars: SEM, CBF: cerebral blood ﬂow, pio: pioglitazone, WT: wild-type.
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Fig. 3. Brain volume was overall increased in APP mice compared to WT. Percent change
in volume of the 64 segmented brain structures in APP mice compared to WT controls.
(☐) q-value N 0.05, no change fromWT; ( ) q-value b 0.05, volume decrease fromWT;
( ) q-value b 0.05, volume increase from WT. Error bars: 95% conﬁdence interval, WT:
wild-type.
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evidenced by signiﬁcantly (p b 0.05) diminished learning capacity in
these mice over the ﬁve-day training period (slope = −1.82 ± 1.23)
compared to WT mice (slope = −5.02 ± 0.69) (Fig. 2C). Moreover,
in the probe trial, crossings at the target location (Fig. 2E), and the per-
cent distance travelled in the target quadrant (Fig. 2F) byAPPmicewere
signiﬁcantly less (p b 0.01 and p b 0.05, respectively) thanWT controls,
consistent with reported deﬁcits in memory retrieval and precision in
these mice. These ﬁndings were not due to differences in swim speed,
which was comparable amongst all groups (data not shown).
3.2.2. Drug effect
Pioglitazone had no effect in WT mice on non-spatial and spatial
MWM aswell as in theprobe trial (Fig. 2). In the spatialMWM, a progres-
sive decrease in average escape latency following blocks of training tri-
als was observed in pioglitazone-treated, but not in untreated APPmice
(Fig. 2B). This was conﬁrmed by analysis of the learning capacity in
pioglitazone-treated APP mice (slope = −5.28 ± 0.94), which was
improved to WT capacity (Fig. 2C). Accordingly, a decrease in the aver-
age distance swam per training day was observed in pioglitazone-
treated, but not in untreated APP mice, reaching signiﬁcance on day 5
(p b 0.01, Fig. 2D). Overall, the spatial training ﬁndings demonstrate
that pioglitazone slightly improves spatial learning in APP mice. In the
probe trial, pioglitazone-treated APP mice performed better than
untreated APP mice in the number of platform crossings, but this mea-
sure failed to reach signiﬁcance (Fig. 2E). The percent distance travelled
in the target quadrant by pioglitazone-treated APP mice was not signif-
icantly different from WT controls (Fig. 2F). Interestingly, percent dis-
tance travelled in quadrant 3 (Fig. 2G) was signiﬁcantly greater in
treated compared to untreated APP mice (p b 0.01). This was reﬂective
of the swim path used by pioglitazone-treated APP mice, which was
largely restricted to quadrant 3 and the target quadrant, a ﬁnding that
contrasted with the ineffective routes swam by untreated APP mice
(Fig. 2G). Overall, the probe-trial ﬁndings show that pioglitazone exerts
a mild beneﬁcial effect on spatial memory-recall in APP mice.
3.3. Neuroanatomical differences in naïve APP and WT mice
3.3.1. Genotype effect
3.3.1.1. Region of interest (ROI) or brain substructure-based volume
analyses. At 6-months of age, the average overall brain volume was 3.2%
larger in APP mice (458.0 ± 18.5 mm3) compared to age-matched WT
controls (443.1 ± 12.1 mm3, p b 0.0001). Volumetric analyses of 64
segmented brain structures revealed that 6 of 64 (9.3%) structures were
signiﬁcantly smaller, while the majority, i.e. 35 of 64 (54.7%) were sig-
niﬁcantly larger in APP mice compared to WT controls (Fig. 3). The
greatest percent volume decrease (4.3%) in APP mice was in the
habenular commissure, whereas the greatest increase (13.3%) was in
the amygdala. Signiﬁcant volume decreases were also observed in the
interpeduncular nucleus, superior olivary complex,mammillary bodies,
corticospinal tract pyramids, and cerebellar cortex. Interestingly, vol-
umes of hippocampal regions including dentate gyrus, CA1, CA2, and
CA3, as well as cortical structures involved in memory processing such
as the entorhinal, temporoparietal, and frontal cortices were larger in
APP mice.
3.3.1.2. Deformation based morphometry (DBM) — local volumetric
analyses. Voxel-wise analysis provides ameasure of local volumetric ex-
pansion (N0) or contraction (b0) relative to the reference space. A key
feature of this approach is that it can detect small focal volume differ-
ences that may not be picked up in brain substructure-based ap-
proaches. Fig. 4C illustrates the differences found between APP and
WT mice, with the red color scale indicating degrees of volume expan-
sion, and the blue scale indicating degrees of volume contraction.
Broad areas of volume expansion can be seen, in line with the overalllarger brains seen in the APP mice. Focal regions of volume contraction
in APP relative toWTwere found in corpus callosum and cingulumbun-
dle, hippocampus (in particular, CA1 region adjacent to themidline, and
CA3) and cerebellar cortex. It should be noted that while volume de-
crease in CA1 spanned almost the entire hippocampal septotemporal
axis, in CA3 it was limited to the intermediate portion. Volume contrac-
tion in the corpus callosum and hippocampal CA1 subﬁeld in APP mice
Fig. 4. Focal hippocampal volume increase associatedwith spatial learning andmemory inWTmice is attenuated in APPmice. (A) Location of theﬁveMRI slices shown in reference to the
3D brain. (B) Population-speciﬁc 3DMRI brain atlas. (C) Effect of genotype on local brain volume.Warm colors correspond to regionswhere APP brains were larger thanWTwhereas cool
colors indicate regions that were smaller. The expansion/contraction map is masked based on statistical signiﬁcance at a false discovery rate (FDR) of 10%. Cross-hairs 1 and 2 point to
speciﬁc areas that are smaller in APP brains compared to WT, namely, the corpus callosum/cingulum bundle and the midline-adjacent CA1 regions, respectively. Cross-hair 3 points to
an area of no change, speciﬁcally, the lateral CA1 region. (D) Expansion/contraction associated with spatial vs. non-spatial learning and memory in WT mice (masked at 10% FDR).
Cross-hair 4 points to volume increase in the CA1/CA2 boundary region. (E) Expansion/contraction associatedwith spatial vs. non-spatial learning andmemory in APPmice (same signiﬁcance
mask as in (D)). Compared to WT mice, APP mice display attenuated hippocampal volume increase following spatial Morris Water Maze performance. (F) The bar graphs show mean and
standard error for the expansion/contraction factor associatedwith each selected voxel (cross-hairs c1–3 and d4). The genotype plots (1–3) have been normalized such that theWT homecage
controls have a factor of 1.0. The training effect plots (4) have been normalized such that the homecage controls for respective genotypes have a factor of 1.0. WT: wild-type.
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the cellular basis of the volume differences in the hippocampus, we
performed histology on sections of the CA1 subﬁeld.
3.3.1.3. Histochemical analyses. Qualitatively, Nissl-stained sections re-
vealed irregular spreading of the CA1 pyramidal cells adjacent to the
midline into the stratum oriens in 6-month-old APP mice (Fig. 5A). In
contrast, there was a sharp demarcation between the CA1 pyramidal
cell layer and stratum oriens in WT mice (Fig. 5A). Quantitatively, the
percent area of the ROI occupied by cell bodies, and the average number
of cells, were signiﬁcantly reduced (p b 0.05) in APPmice (18.2 ± 2.4%
and 188.1 ± 22.1, respectively) compared toWT controls (28.8 ± 0.4%
and 329.5 ± 33.4, respectively) (Fig. 5B, C). The average cell size did notdiffer between APP (198.9 ± 5.0 μm2) and WT (183.1 ± 15.2 μm2)
mice. As a negative control, we performed similar histochemical analy-
ses on the lateral region of the CA1, which did not exhibit focal volume
decrease (Fig. 4C,F), and found no qualitative (Fig. 5D) nor quantitative
differences (Fig. 5E, F) between APP and WT mice.
3.3.1.4. Whole brain cortical thickness analyses. 6-month-old APP andWT
mice exhibited differences in regional cortical thickness. In comparison
to 6-month-oldWTmice, increase in cortical thickness was observed in
the frontal association areas, anterior cingulate, retrosplenial, entorhi-
nal, perirhinal, and primary visual cortices of 6-month-old APP mice
(Fig. 6A). The greatest percent cortical thickness increase in APP mice
was in the lateral part of the entorhinal cortex (+15.6%; means,
Fig. 5. Alterations in midline-adjacent CA1 area of the hippocampus in APP mice. (A) Nissl-stained hippocampal sections reveal disorganization of cells in the midline-adjacent CA1
pyramidal layer in 6-month-old APP mice. (B) Compared to age matched control ( ) and pioglitazone-treated ( ) WT mice, the area occupied by cell bodies is signiﬁcantly reduced in
control ( ) and pioglitazone-treated ( ) APP mice. (C) Similarly, irrespective of pioglitazone-treatment status, the average number of cells is signiﬁcantly lower in APP mice compared
toWTmice. (D) No qualitative differencewas observed in the lateral CA1 region between 6-month-old APP andWTmice. Quantitatively, (E) the area occupied by cell bodies in the lateral
CA1 region, and (F) the average numbers of cells were not signiﬁcantly different between APP and WT mice. Statistical analysis used was a two-way ANOVA. Scale bars: 1 mm (low
magniﬁcation images), 0.05 mm (high magniﬁcation images). p b .01, p b .001. Error bars: SEM, pio: pioglitazone, WT: wild-type.
Fig. 6. Cortical thickness differences by genotype. (A) F-Statistic maps were thresholded at a false discovery rate of 5%. Red is APP N WT, blue isWT N APP. Thickness differencesmax out
at 0.1 mm. (B) Percent change in cortical thickness of six regions in APP mice compared to WT controls. ENTl: entorhinal cortex (lateral part), FRA: frontal association cortex, ECT/PERI:
ectorhinal/perirhinal cortex, VISp: primary visual cortex, ACA: anterior cingulate cortex, MOp: primary motor cortex, RSP: retrosplenial cortex, WT: wild-type. Brain structure abbreviations
used are from the Mouse Allen Reference Atlas available online at http://www.brain-map.org.
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frontal association areas (+8.6%; means, 1.16 ± 0.004 mm WT and
1.26 ± 0.007 mm APP), while a reduction (−4.9%; means, 1.42 ±
0.004 mm WT and 1.35 ± 0.006 mm APP) was seen in the primary
motor cortex of APP mice (Fig. 6B).
3.3.2. Drug effect
No signiﬁcant differences in the volume of brain structures or corti-
cal thickness were detected in pioglitazone-treated APP and WT mice
compared to their respective untreated controls. In linewith the overall
lack of treatment-effect on brain structure volumes, Nissl-staining did
not detect any qualitative (Fig. 5A, D) nor signiﬁcant quantitative
(Fig. 5B, C, E, F) differences in the hippocampal CA1 subﬁeld between
pioglitazone-treated APP and WT mice compared to their respective
untreated controls. Moreover, consistent with no treatment effect on
brain volume and with earlier ﬁndings in old APP mice (Nicolakakis
et al., 2008), there was also no difference in the Aβ plaque load in the
hippocampus between pioglitazone-treated and untreated APP mice
(Fig. 7).
3.4. Brain volume differences between spatial and non-spatial MWM
3.4.1. Genotype effect
To test whether the response to spatial training differed by geno-
type, we computed separate voxel-wise linear models relating local
brain volume to MWM (i.e. spatial vs. non-spatial). DBM analyses of
WT mice that had performed the spatial MWM compared to those that
performed the non-spatial MWM revealed signiﬁcant focal volume in-
crease (6%) in a contiguous region of the hippocampus beginning ros-
trally at the CA1/CA2 boundary region and extending caudally along
both CA1 and CA2 (Fig. 4D). The increase in volume was lateralized to
the left dorsal hippocampus. In comparison, for the same contrast in
APP mice, focal volume increase in the CA1/CA2 boundary region was
reduced (3.8%) relative to that seen in WT mice (Fig. 4E). The training
effect remained signiﬁcant in the WT mice, whereas the effects in the
APP did not survive multiple comparison correction (Fig. 4F). Outside
the hippocampus, signiﬁcant focal volume increases were observed in
the corpus callosum and cingulum bundle, entorhinal cortex, and the
cerebellum of WT mice that had undergone the spatial MWM (Fig. 4D).Fig. 7. Pioglitazone did not reduce Aβ plaque load in the hippocampus. Qualitatively, the area
occupied by thioﬂavin S-stainedmature, dense-core amyloid plaques in the hippocampus of
6-month-old (A) APPmice and (B) pioglitazone-treated APP (APP (pio)) mice were compa-
rable. (C) Quantitatively, pioglitazone-treatment did not reduce amyloid plaque load. Scale
bar: 1 mm (4× zoom), error bars: SEM, pio: pioglitazone.3.4.2. Drug effect
No signiﬁcant focal brain volume differences were observed in
pioglitazone-treated WT or APP mice undergoing spatial versus
non-spatial MWM.
4. Discussion
4.1. Mutated-hAPP overexpression induces neuroanatomical reshaping
4.1.1. Brain structure volume abnormalities
Weﬁnd that brain volume is abnormal in 6-month-oldAPPmice,with
both atrophy and hypertrophy present at the level of the brain substruc-
tures. Brain atrophy, both global and regional, is a hallmark feature of AD.
Interestingly, the majority of atrophied structures identiﬁed in APP mice,
namely thehabenular commissure, interpeduncular nucleus,mammillary
bodies, and cerebellar cortex are emerging extrahippocampal players in
spatial memory processing (Bianco and Wilson, 2009; Kobayashi et al.,
2013; Rochefort et al., 2013; Vann andAggleton, 2003). Volumedecreases
in the latter two structures has also been reported in AD patients
(Andersen et al., 2012; Copenhaver et al., 2006; Wegiel et al., 1999).
In contrast, the observation that themajority of brain-substructures,
including the hippocampus, are hypertrophic in APP mice is unexpect-
ed, but has precedent. Similar observations of regional brain volume
hypertrophy have been reported in pre-symptomatic familial ADmuta-
tion carriers (Fortea et al., 2010; Lee et al., 2013) and in 6-month-old
APP(Swe)/PS1(M146V) mice on the same C57BL/6J background as our
mice (Maheswaran et al., 2009). Possible mechanisms accounting for
regional brain volume increase in mouse models of familial AD include
(a) the space-occupying effects of Aβ-deposits, and soluble/deposited
Aβ-induced inﬂammatory response (e.g. gliosis and edema) in the ab-
sence of brain tissue loss (Fox et al., 2005; Maheswaran et al., 2009);
(b) hAPP overexpression-induced increase in neurogenesis (Jin et al.,
2004), and/or a shift in the distribution of neuronal cell size toward
larger neurons (Oh et al., 2009); and (c) compensatory neuronal hyper-
trophy, an early cellular attempt at offsetting neuronal injury induced
byAβ (Driscoll and Troncoso, 2011).While the latter requires investiga-
tion inmurineADmodels, cortical and hippocampal neuronal hypertro-
phy has been demonstrated in asymptomatic AD cohorts from the
Baltimore Longitudinal Study of Aging (O'Brien et al., 2009; Riudavets
et al., 2007) and the Nun Study (Iacono et al., 2009).
The variability in global and regional brain volume differences re-
ported in APP mouse models, ranging from atrophic (Badea et al.,
2010; Lau et al., 2008; Redwine et al., 2003) to hypertrophic could be
explained, in part, by variations in transgene(s) combination, promoter
used for hAPP expression, the number and location of hAPP muta-
tion(s), and genetic background. These variables impactAPP expression,
soluble and deposited Aβ-levels, and Aβ-related neuroinﬂammation and
oxidative stress indices (Crews et al., 2010; Scahill et al., 2013). These fac-
tors, togetherwith age,method and locus ofmeasurement, likely explain
the observed variability in mutated-hAPP overexpression-induced neu-
roanatomical reshaping.
4.1.2. Focal brain volume differences
Voxel-wise DBM analysis demonstrated broad areas of volume ex-
pansion and selective areas of contraction in the 6-month-old APP
brain, generally consistentwith the brain structure-level analysis. How-
ever, voxel-level analysis revealed small areas of focal volume decreases
bilaterally within the otherwise hypertrophic hippocampal subﬁelds
CA1 and CA3, with atrophy more spatially extensive within CA1. Our
ﬁnding in APP mice is consistent with the MRI-detectable sub-regional
CA1 volume decreases apparent in early AD (Frisoni et al., 2008;
Kerchner et al., 2010). Previous work from our group using the same
analysis procedure to compare ex vivo and in vivo MRI data found
good agreement in brain morphology, supporting the interpretation of
the observed changes as focal volume changes rather than local effects
of ﬁxation (Lerch et al., 2012).
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the hippocampal subﬁelds of APP mice, we performed histopathology
on the locus in CA1 and demonstrated signiﬁcantly low cell counts
and disorganization of pyramidal layer (CA1sp) neurons. Neuron loss
in the CA1, in particular the CA1sp, has been documented in AD patients
(Davies et al., 1992). Loss of septal CA1 neurons was recently found in
6-month-old J20 APP mice using ROI-based stereological methods
(Wright et al., 2013). Our study extends this ﬁnding by demonstrating
that at this age, neuron loss in the CA1, especially that in the CA1sp, is
selective to medial CA1 and spans almost the entire hippocampal
septotemporal axis. In summary, since both CA1 and CA3 neurons are
critically involved in spatial learning/memory in rodents (Florian and
Roullet, 2004; Maviel et al., 2004) and humans (Holden et al., 2012;
Suthana et al., 2009), the mutated hAPP-speciﬁc localized hippocampal
atrophy most likely contributes to impaired spatial MWM performance
in our APP mice.
Outside the hippocampus, we demonstrated bilateral focal volume
decreases within the cerebellar cortex, an extrahippocampal substrate
for spatial cognition (Rochefort et al., 2013). Sub-regional volume de-
creases were also observed in the anterior part of the medial and lateral
white matter (WM) tracts, speciﬁcally, the cingulum (CG) and underly-
ing corpus callosum (CC). In rodents, CG and CC lesions impair spatial
behaviour (Aggleton et al., 1995), including spatial MWM performance
(Warburton et al., 1998). Volumetric reductions in CG (Villain et al.,
2008) and CC (Di Paola et al., 2010) also occur in MCI and AD patients.
4.1.3. Aberrant cortical thickness
Using an automated algorithm to measure thickness across the
entire cortex, we demonstrate that cortical thickness is aberrant in
6-month-old APP mice. Since APP is a crucial player in processes con-
trolling cortical development (Herms et al., 2004) mutated-hAPP
overexpression may be a factor in the abnormal cortical phenotype in
APP mice. Cortical thickening was present in the entorhinal, perirhinal,
retrosplenial, anterior cingulate, and frontal association cortices, all
key neocortical structures involved in spatial learning/memory (Vann
and Albasser, 2011). While unexpected in the AD literature, cortical
thickening has been reported in middle-aged apolipoproteinEε4 indi-
viduals, negatively impacting their spatial-cueing (Espeseth et al.,
2010), and pre-symptomatic familial AD presenilin-1 mutation carriers
(Fortea et al., 2010). This group then observed an inverted U-shaped re-
lationship between cortical thickness and CSF-Aβ42 levels, suggesting
that pathological increases in cortical thickness may precede thinning
as Aβ-plaques accumulate in the brain (Fortea et al., 2011). Recent
in vivo work in J20 APP mice supports the idea of a temporal evolution
of cortical thickness abnormalities, with aberrant thickening of the re-
gions involved in spatial memory/learning occurring between 1 and
3 months of age (Grand'maison et al., 2013; Hebert et al., 2013). Our
current results suggest that these same cortical regions remain abnor-
mally thick at least until 6 months of age, when Aβ deposition and spa-
tial memory deﬁcits have just been established. The greater rate of
cortical thinning evident in these mice by 12-months, compared to
age-matched WT controls (Hebert et al., 2013), is reminiscent of the
cortical thickness pattern observed in familial AD mutation carriers
(Fortea et al., 2010) with a transitory thickening preceding thinning as-
sociated with disease progression.
4.2. Mutated-hAPP attenuates learning and memory-induced
neuroanatomical plasticity
We found that in 6-month-old WTmice, successful spatial learning/
retrieval induced robust volume increases within the hippocampus.
These increaseswere localized to a contiguous region beginning rostral-
ly at the CA1/CA2 boundary-region and extending caudally along CA1
and CA2, consistent with the effect of spatial MWM on dorsal hippo-
campal volume that we observed in 3-month-old WT mice (Lerch
et al., 2011a). The magnitude of this increase was greatly reduced inthe CA1/CA2 boundary-region of age-matched APPmice, a ﬁnding con-
sistent with their poor spatial MWM performance. Three lines of evi-
dence support our MRI-based neuroanatomical plasticity ﬁndings in
WT mice. Lesion-based research in rats shows that dorsal, but not ven-
tral, hippocampal lesions impair acquisition on the spatial MWM
(Moser et al., 1995). Enhanced metabolic activity in rostral CA1,
extending caudally, has been demonstrated inmice following spatial ra-
dial arm maze (Ros et al., 2006). Electrophysiological studies have
shown that the dorsal hippocampus houses a higher proportion of
place cells (cells responding to spatial information), and focused place
ﬁelds compared to its ventral counterpart (Jung et al., 1994). Ourﬁnding
of left-lateralization of volume increase in the CA1/CA2 boundary-
region is further supported by studies demonstrating that left, but not
right, hippocampus inactivation prior to spatial MWM training weak-
ened rodent probe-trial performance (Klur et al., 2009), and that
virtual-spatial MWM learning in human increased left-anterior hippo-
campal activity (Cornwell et al., 2008). Since, these ﬁndings suggest
that the left hippocampus facilitates spatial memory encoding/consoli-
dation and the right aids memory-retrieval, it appears that attenuated
hippocampal plasticity in APP mice perturbs the former process.
4.3. Effect of pioglitazone-treatment
4.3.1. Pioglitazone abrogates mutated-hAPP-induced cerebrovascular
dysfunction
We show that neuronal activity-evoked CBF response in the somato-
sensory area of the neocortex was impaired in young APP mice prior to
amyloid plaque deposition (Mucke et al., 2000) and measurable mne-
monic impairment (DeIpolyi et al., 2008), and persisted into adulthood.
We demonstrate that pioglitazone counters this chronic cerebrovascu-
lar insufﬁciency as early as 3 days into treatment. This study extends
our previous ﬁndings of beneﬁcial effects of short-term pioglitazone-
treatment on stimulus-induced increases in cerebral perfusion and glu-
cose metabolism, and cerebrovascular reactivity in aged APP mice
(Nicolakakis et al., 2008). Together, the results conﬁrm that cerebrovas-
cular insufﬁciency, in particular reduced baseline (Hebert et al., 2013;
Niwa et al., 2002) and stimulus-evoked CBF (Niwa et al., 2000), is an
early pathogenic marker found in various APP mouse models of AD.
Our study also indicates that pioglitazone is a potent reverser of cere-
brovascular dysfunction at all stages of Aβ-induced pathology in APP
mice. It thus has the potential to alleviate the chronic cerebrovascular
insufﬁciency observed in AD (Chen et al., 2011; Iadecola, 2004;
Rodriguez et al., 2000; Zlokovic et al., 2005). Supporting our hypothesis
is the ﬁnding that daily pioglitazone intake for 6 months improves pari-
etal lobe CBF in mild AD patients with T2DM (Sato et al., 2009).
4.3.2. Pioglitazone exerts beneﬁcial effects on spatial learning and memory
We found that long-term pioglitazone-treatment commencing in
young APP mice improved spatial learning capacity to WT levels, and
exerted a mild positive effect on memory recall in adult APP mice. The
beneﬁcial effect on cognition may be due to the combined ability of
pioglitazone to sustainably abrogate cerebrovascular dysfunction starting
in youngmice and, as previously demonstrated, reduce indexes of neuro-
nal dysfunction such as cerebral oxidative stress, glial activation, and cho-
linergic denervation (Nicolakakis et al., 2008). However, it is also possible
that the limited beneﬁts of pioglitazone on cognitive function occur inde-
pendently from the CBF improvements. In the AD literature to date,
pioglitazone has been shown to improve regional CBF and cognitive func-
tion in mild AD patients with T2DM (Sato et al., 2009), and has been rec-
ommended for testing in earlier disease stages of AD (Geldmacher et al.,
2011). A clinical trial testing the ability of a low dose of pioglitazone to
delay the onset of MCI of the AD type is expected to launch this year
(Crenshaw et al., 2013).
Pioglitazone treatment did not improve learning/memory-induced
neuroanatomical plasticity and hAPP-induced aberrant neuroanatomi-
cal reshaping, supporting the notion that the substrate for cognitive
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address multiple root causes to achieve the best outcomes.
5. Conclusions
In summary, overexpression of mutated-hAPP inmice induces aber-
rant neuroanatomical reshaping, cerebrovascular dysfunction, deﬁcits
in spatial learning/memory and associated neuroanatomical plasticity.
Early, long-term intervention with pioglitazone rescues brain hemody-
namics and exerts positive effects on spatial learning and memory.
Since treatment of vascular risk factors and/or vascular co-morbidities
has been shown to slow cognitive decline (Deschaintre et al., 2009; Li
et al., 2011), pioglitazone may be of beneﬁt to AD patients with concur-
rent cerebrovascular deﬁcits. Absence of a corresponding recovery in
neuroanatomical plasticity in treated APP mice with normalized func-
tional hyperemia implicates impaired neuroanatomical plasticity as an
additional factor contributing to cognitive deﬁcits, possibly deﬁning a
new therapeutic target.
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